Droperidol

Droleptan, Droperidol (Medsurge), Droperidol (Panpharma)

Strength

0.5 mg/mL (volume: 3 mL)

1.25 mg/mL (volume: 1 mL)

2.5 mg/mL (volume: 1 mL, 2 mL)

IV administration

Give undiluted or dilute to a convenient volume and give over 2 to 5 minutes.

Alternatively, dilute to 0.1 to 0.25 mg/mL and give over 20 minutes.

Other routes of administration

IM: Suitable.

SC: Not recommended.

Compatible IV fluids

Sodium chloride 0.9% 

Droperidol 0.25 mg/mL or weaker:

Glucose 5%

Hartmann’s

Y-site only and droperidol 1.25 mg/mL or weaker:

Potassium chloride 20 mmol/L

Additional information

Monitor ECG prior to use.

Patients at risk of QT prolongation: Monitor ECG before, during and for 2 to 3 hours after administration.

Use IV route only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.

IV administration is associated with a greater risk of QT prolongation. Contraindicated in patients predisposed to QT interval prolongation or in patients being administered other medications known to prolong the QT interval.

May lower the seizure threshold; use cautiously in patients with seizure history.

Concomitant use of CNS depressants (e.g. opioids, parental benzodiazepines, IM olanzapine) increases the risk of respiratory depression, sedation, coma and death.

Protect from light during storage.